Richard Gelb, MD
Interventional Cardiology · Orem, UTNPI 1063442523
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,454 of the $5,469 with a category attached, or 81.4%. 30 manufacturers reported payments, led by Boston Scientific at 29.3% of the total. Reporting peaked in 2024 at $2,320 and has fallen 92.5% since, to $174 in 2025. That places this record below the midpoint for interventional cardiology clinicians in UT, where the typical reported total is $5,946.
Across 210 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Novartis$847
- Johnson & Johnson$402
- Merck$370
- Amgen$353
- Pfizer$348
- plus $2K from 24 others
What the payments were for
- Travel & lodging$99018%
- Food & beverage$4,45481%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $1,602 |
| Novartis | 44 | $847 |
| Johnson & Johnson(2 entities) | 22 | $402 |
| Merck | 20 | $370 |
| Amgen | 18 | $353 |
| Pfizer | 17 | $348 |
| Medtronic(2 entities) | 6 | $147 |
| Abbott | 4 | $135 |
| Amryt Pharma Holdings Ltd | 6 | $113 |
| Endologix LLC | 2 | $111 |
| Irhythm Technologies, Inc. | 4 | $107 |
| Boehringer Ingelheim | 7 | $106 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| AstraZeneca | 7 | $95 |
| Bayer | 6 | $85 |
| Actelion Pharmaceuticals US, Inc. | 4 | $79 |
| Lexicon Pharmaceuticals, Inc. | 3 | $75 |
| Esperion Therapeutics, Inc. | 4 | $64 |
| Heartflow, Inc. | 3 | $55 |
| Chiesi USA, Inc. | 2 | $45 |
| Cvrx, Inc. | 2 | $41 |
| Livanova USA, Inc. | 1 | $34 |
| Baxter Healthcare | 1 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Penumbra, Inc. | 1 | $21 |
| Abiomed | 1 | $16 |
| Shockwave Medical, Inc | 1 | $16 |
| Aegerion Pharmaceuticals, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
How this compares
$5,469 in reported general payments places this provider in the 45th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $150,856 |
| XareltoRivaroxaban | 52 | $75,243 |
| EntrestoSacubitril/Valsartan | 52 | $69,089 |
| FarxigaDapagliflozin Propanediol | 40 | $39,985 |
| Repatha SureclickEvolocumab | 48 | $34,669 |
| JardianceEmpagliflozin | 32 | $32,918 |
| OzempicSemaglutide | 25 | $28,728 |
| Repatha SyringeEvolocumab | 21 | $10,019 |
| Atorvastatin Calcium | 312 | $3,616 |
| Metoprolol Succinate | 216 | $2,811 |
| Rosuvastatin Calcium | 149 | $2,315 |
| Digoxin | 11 | $2,079 |
| Carvedilol | 157 | $1,301 |
| Potassium Chloride | 56 | $1,199 |
| Losartan Potassium | 110 | $1,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $348 | $150,856123 claims |
| Johnson & JohnsonXarelto | $402 | $75,24352 claims |
| NovartisEntresto | $847 | $69,08952 claims |
| AstraZenecaFarxiga | $95 | $39,98540 claims |
| Boehringer IngelheimJardiance | $106 | $32,91832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 45 interventional cardiology providers in Utah.
Other interventional cardiology in Orem
- Rodney BadgerOrem$11K
- Vamsee YagantiSalt Lake City$390K
- Blake GardnerSt George$267K
- Anwar TandarSalt Lake City$131K
- Sanjeev TrehanOgden$95K
- Stavros DrakosSalt Lake City$79K
- Tareq HarbOgden$27K
- Frederick WeltSalt Lake City$26K
- Jared CrisafiSt George$24K
- Scott HackingSalt Lake City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.